Next Monday we are hosting a group of researchers from the Laboratory of BioNanoTechnology at Wageningen University. Join us for an engaging morning of scientific exchange, with presentations from both … Read more
The new AI is able to predict when and why protein aggregation occurs, a mechanism linked to Alzheimer’s and 50 other diseases that affect 500 million people. The results show great potential for research into neurodegenerative diseases and for improving drug production, reducing costs and increasing efficiency. The study, published today in Science Avances, is the result of a collaboration between the Centre for Genomic Regulation (CRG) and the Institute of Bioengineering of Catalonia (IBEC).
Ref: PhD-PG // Deadline: 12/05/2025
El IBEC es el coorganizador de la Jornada Anual de este año, que se celebrará el próximo 17 de junio y lleva como título ‘Investigación traslacional en tecnología y salud’. La … Read more
The Bioengineering in the Territory project aims to decentralize scientific knowledge and promote scientific education in an equitable way across the region. We want to ensure that everyone, regardless of … Read more
The Atomic Force Microscopy in Life Sciences and Nanomedicine (AFM BioMed) conference took place in Barcelona last week. The 2025 edition, which brought together 160 participants, was organised by the … Read more
Ref: PhD- IM // Deadline: 25/04/2025
A study led by the University of Barcelona in collaboraiton with the Institute for Bioengineering of Catalonia reveals that the functional assay dynamic BH3 profiling (DBP) can predict whether specific treatments will be effective in non-small cell lung cancer patients. The technique helps determine which therapy will be most effective by testing it directly on living cells, improving personalised therapies.
Dr Irene Marco-Rius, principal investigator at the Institute for Bioengineering of Catalonia (IBEC), has been awarded the 2025 Anatole Abragam Prize for her pioneering work on the use of magnetic resonance to study cells grown on chips, allowing ex vivo metabolic assessment of disease mechanisms and therapy responses in controlled microenvironments. The award was presented at the Joint ENC-ISMAR Conference in California.